Recombinant human ACE2: potential therapeutics of SARS-CoV-2 infection and its complication

Acta Pharmacol Sin. 2020 Sep;41(9):1255-1257. doi: 10.1038/s41401-020-0430-6. Epub 2020 Jun 24.
No abstract available

Publication types

  • Letter

MeSH terms

  • Angiotensin-Converting Enzyme 2
  • Antiviral Agents / metabolism
  • Antiviral Agents / pharmacology
  • Betacoronavirus* / drug effects
  • Betacoronavirus* / physiology
  • COVID-19
  • Coronavirus Infections* / drug therapy
  • Coronavirus Infections* / metabolism
  • Coronavirus Infections* / physiopathology
  • Drug Development
  • Drug Discovery*
  • Humans
  • Pandemics*
  • Peptidyl-Dipeptidase A* / metabolism
  • Peptidyl-Dipeptidase A* / pharmacology
  • Pneumonia, Viral* / drug therapy
  • Pneumonia, Viral* / metabolism
  • Pneumonia, Viral* / physiopathology
  • Recombinant Proteins
  • SARS-CoV-2
  • Sequence Alignment
  • Spike Glycoprotein, Coronavirus / genetics
  • Virus Internalization / drug effects

Substances

  • Antiviral Agents
  • Recombinant Proteins
  • Spike Glycoprotein, Coronavirus
  • Peptidyl-Dipeptidase A
  • ACE2 protein, human
  • Angiotensin-Converting Enzyme 2